About ProAxsis
ProAxsis is a company based in Belfast (United Kingdom) founded in 2013 by Lorraine Martin and Brian Walker was acquired by NetScientific in October 2020.. ProAxsis has raised $2.79 million across 6 funding rounds from investors including European Union, EMV Capital and AB Group. ProAxsis offers products and services including NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology. ProAxsis operates in a competitive market with competitors including Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Eclipse Bio, among others.
- Headquarter Belfast, United Kingdom
- Founders Lorraine Martin, Brian Walker
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Proaxsis Ltd
- Date of Incorporation 16 Aug, 2013
- Jurisdiction BELFAST, NORTHERN IRELAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.79 M (USD)
in 6 rounds
-
Latest Funding Round
$298.56 K (USD), Seed
Jul 07, 2025
-
Investors
European Union
& 3 more
-
Employee Count
Employee Count
-
Acquired by
NetScientific
(Oct 16, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ProAxsis
ProAxsis offers a comprehensive portfolio of products and services, including NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Detects active neutrophil elastase for respiratory disease diagnostics.
Assay for detecting active proteinase biomarkers in chronic conditions.
Enables protease detection in ELISA and lateral flow devices.
Unlock access to complete
Unlock access to complete
Funding Insights of ProAxsis
ProAxsis has successfully raised a total of $2.79M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $298.56 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Seed — $298,558
-
First Round
First Round
(21 Feb 2014)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Seed - ProAxsis | Valuation |
investors |
|
| Apr, 2024 | Amount | Seed - ProAxsis | Valuation |
investors |
|
| Feb, 2023 | Amount | Debt – Conventional - ProAxsis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ProAxsis
ProAxsis has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EMV Capital and AB Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in deep tech and life sciences by EMV Capital.
|
Founded Year | Domain | Location | |
|
AB Group is engaged in managing retail construction and refurbishment projects.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ProAxsis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ProAxsis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Proaxsis Comparisons
Competitors of ProAxsis
ProAxsis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Eclipse Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of immunoassays for diagnostic purposes
|
|
| domain | founded_year | HQ Location |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| domain | founded_year | HQ Location |
Provider of products and services for human protein biomarker research and development
|
|
| domain | founded_year | HQ Location |
An in vitro assay platform is provided for diagnostic solutions.
|
|
| domain | founded_year | HQ Location |
Cell-free immunoassays are developed to identify RNA binding protein targets.
|
|
| domain | founded_year | HQ Location |
Correlia Biosystems is focused on protein quantification technology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Proaxsis
Frequently Asked Questions about ProAxsis
When was ProAxsis founded?
ProAxsis was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is ProAxsis located?
ProAxsis is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
Who is the current CEO of ProAxsis?
David Ribeiro is the current CEO of ProAxsis.
Is ProAxsis a funded company?
ProAxsis is a funded company, having raised a total of $2.79M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $599.78K, raised on Feb 21, 2014.
What does ProAxsis do?
ProAxsis was founded in 2013 in Belfast, United Kingdom, within the biotechnology sector. ProteaseTags, an active neutrophil elastase immunoassay, have been developed to bind and quantify the activity of specific proteases in complex biological samples. Services provided include clinical research support, biomarker development, and academic collaborations, with operations focused on diagnostic and research applications in healthcare.
Who are the top competitors of ProAxsis?
ProAxsis's top competitors include Abingdon Health, Eclipse Bio and Spear Bio.
What products or services does ProAxsis offer?
ProAxsis offers NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology.
Who are ProAxsis's investors?
ProAxsis has 4 investors. Key investors include European Union, EMV Capital, AB Group, and EIC Fund.